Latest Typical antipsychotic Stories

2009-08-14 06:00:00

KENILWORTH, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S.

2009-07-30 06:30:30

Older diabetic patients who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia (elevated blood glucose level), especially soon after beginning treatment, according to a new report.

2009-05-19 13:56:00

SAN FRANCISCO, May 19 /PRNewswire/ -- New data demonstrate that maintenance therapy with RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to placebo in patients with Bipolar I Disorder.

2009-05-19 06:57:00

SAN FRANCISCO, May 19 /PRNewswire/ -- Schizophrenia is one of the most disabling diseases,(1) and frequent relapses and rehospitalization as a result of the disease place enormous burdens on patients, caregivers and society.(2) According to two new studies, the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) may improve clinical and functional outcomes and reduce rates of rehospitalization among patients with schizophrenia.

2009-05-18 12:30:00

Three-year data show olanzapine LAI safety findings consistent with oral olanzapine except for injection-related events INDIANAPOLIS, May 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company presented today data on the short- and long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of adults with schizophrenia or schizoaffective disorder.

2009-05-06 16:53:29

The U.S. Food and Drug Administration has approved Fanapt tablets to treat adults with schizophrenia, a chronic, severe and disabling brain disorder. Schizophrenia can be a devastating illness requiring lifelong treatment and therapy, said Dr.

2009-01-07 17:12:00

INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it received a complete response letter from the U.S.

2008-12-10 07:30:00

Results of Two Trials Identify Potential Initiation Dosing Regimen TITUSVILLE, N.J., Dec.

2008-10-21 09:00:54

INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it is in advanced discussions to resolve the ongoing investigations led by the U.S. Attorney's Office for the Eastern District of Pennsylvania (EDPA) related to past U.S.